Hot flashes. Disrupted sleep. Mood shifts. Brain fog. They aren’t “just aging.” They’re a protocol — built around your specific biology, your cardiovascular risk, and the way your hormones are actually changing.
Female Hormone Optimization is for women in perimenopause, menopause, and beyond who want a physician who takes the symptoms seriously and builds the protocol from evidence — not from a standard dose.
Sleep fragmented. Mood shifts you don’t recognize. Cycle unpredictable. Your PCP said the labs were “normal” and recommended yoga. You know something is changing. You want a physician who investigates the whole picture and builds a protocol around it.
You’ve read the WHI studies, you’ve read the rebuttals, you’ve read the recent cardiovascular and bone-health literature. You want a physician who takes your cardiovascular risk and VTE (blood clot) history into account — not a template protocol.
You want care that considers your history from the initial evaluation through follow-up and treatment adjustments.
Physician care fee: $149/month. Labs: $50 initial, $50 annual. Medication: billed through the practice with medication management. Three line items, every charge visible, no bundled mystery pricing.
Perimenopause and menopause are clinical diagnoses made from symptom pattern and cardiovascular-risk assessment — not from a single FSH (follicle-stimulating hormone) or estradiol (primary estrogen) measurement. Hormone values in perimenopause can vary substantially over time. A normal FSH on the day your blood was drawn doesn’t rule out the transition. An elevated estradiol doesn’t rule it in. Protocols built primarily around those numbers miss the patient entirely.
Your treating physician builds your HRT protocol from three things: your symptom pattern (what’s changed, how long, how disruptive), your cardiovascular and venous thromboembolism (VTE) history, and the labs that actually inform a safe protocol — metabolic baseline, lipid panel, A1C, and thyroid where clinically indicated. The labs inform your safety assessment. Your symptoms guide treatment decisions.
Endocrine society guidance and the recent perimenopause literature are clear: FSH and estradiol levels in women age 45 and above are too volatile to reliably rule in or rule out the transition. A normal value on one day can be elevated the next. Protocols that hinge on these single values either under-treat symptomatic women (because their labs “look normal”) or over-treat asymptomatic women (because a lab drifted). Evidence-based HRT treats symptoms and risk — not single hormone snapshots.
“Your labs don’t rule out perimenopause. Your physician does.”
HRT protocols require a 6–8 week titration and evaluation window for effects to stabilize and for adjustments to be clinically meaningful. That’s not a marketing window — it’s how the biology actually responds. Your treating physician adjusts the protocol across that window and beyond as your symptoms, your labs, and your life evolve.
Every protocol is built from the combination that fits your symptoms, your risk profile, and your preferences. FDA-approved commercially manufactured hormone products are considered when clinically appropriate. When a compounded hormone is selected for an individualized clinical need, it is sourced through a licensed compounding pharmacy. Compounded preparations are not commercially manufactured drug products. They are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing.
Commercially manufactured FDA-approved products and, when an individualized clinical need supports it, compounded preparations may be considered. Any compounded estrogen preparation is identified as compounded and is not a commercially manufactured drug product.
Daily or weekly depending on format.
Commercially manufactured FDA-approved oral micronized progesterone and, when an individualized clinical need supports it, compounded preparations may be considered. Any compounded progesterone preparation is identified as compounded and is not a commercially manufactured drug product.
Daily, typically at bedtime.
Low-dose topical testosterone may be considered where clinically indicated. This custom-compounded preparation is not a commercially manufactured drug product and is not FDA-approved. Monitoring is included in ongoing physician care.
Daily topical application.
TSH evaluation at baseline. FDA-approved commercially manufactured products are considered first when appropriate. A compounded thyroid preparation may be considered for an individualized clinical need; it is not a commercially manufactured drug product and is not FDA-approved.
Daily.
HRT is safe when the patient is appropriate for it. Cardiovascular risk assessment and venous thromboembolism (VTE) history review are required before treatment initiation — not as a liability exercise, but because the protocol depends on them. Format selection, dose, and route all follow from this assessment.
Labs are ordered through Empower Med and billed at the published patient price. Same panel initial and annual.
FSH · Estradiol — Not routinely measured in women 45+. Volatile and clinically non-specific. Symptom pattern and cardiovascular-risk assessment drive the diagnosis, not a single hormone value.
Physician fee. Labs. Medication. Three separate line items. You see all of them.
HRT and TRT share the same monthly physician care fee. The monitoring details differ, but the physician relationship and ongoing clinical responsibility are the same. Here’s the full breakdown:
| Physician care feeInitial physician evaluation and protocol design, titration across the 6–8 week evaluation window, ongoing adjustment as symptoms and labs evolve, async messaging, thyroid co-management as clinically indicated. | $149/ month |
| Initial lab panelBMP, Lipid Panel, HbA1c — with written physician interpretation and cardiovascular-risk framing. | $50one-time |
| Annual monitoring labsSame panel — BMP, Lipid, HbA1c. | $50/ year |
| Hormone medicationsMedication cost varies by the regimen selected. FDA-approved and, when clinically appropriate and lawful, compounded options may use different dispensing and billing pathways. Any medication charge is itemized separately from the physician care fee. | Variablebilled through practice |
The physician care fee is $149/month. Initial and annual labs are $50 each. Medication is billed separately based on your specific regimen and itemized during protocol design.
Unlike Metabolic (which has a $100 Lab credit) and TRT (which has a $165 Lab credit), HRT does not offer a conversion credit from the Open-Access Lab Service. The reason is clinical, not commercial: perimenopausal women frequently present with normal routine lab values despite genuine symptoms. A lab panel does not predict whether HRT is clinically appropriate for you — your symptoms and cardiovascular-risk assessment do. Incentivizing a lab-first pathway would point patients to a diagnostic that doesn’t actually answer the question. The right entry point for HRT is a physician consultation, not a lab order.
“Your labs don’t rule out perimenopause. Your physician does.”
For patients seeking individualized evaluation, risk assessment, and ongoing physician-directed care.
Request a ConsultationOr reach out directly — info@empowermed.us · (571) 293-6244
